Navigation Links
N30 Pharma Announces Financing, Expansion of Board

BOULDER, Colo., Oct. 28 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that regulate nitric oxide bioavailability, announced today that it has completed a financing and expanded its Board of Directors.

N30 will use proceeds from this financing to advance its clinical program in Cystic Fibrosis and expand its discovery and preclinical research in the area of small molecule drugs that modulate nitric oxide bioavailability in cardiopulmonary diseases. The financing is the company's second since its formation in 2007. Joining the company's Board of Directors are Arnold Snider and Marc Elia. Mr. Snider will assume the role of Chairman of the Board.

Mr. Snider previously founded and managed Deerfield Management, a New York-based multi-billion dollar hedge fund focused on healthcare and life-sciences companies. Mr. Snider is also on the Board of Directors of the Christopher and Dana Reeve Foundation and is a trustee of Davidson College.

Mr. Elia co-founded N30 while at Tiger Management, a New York hedge fund, and has had previous roles in life sciences corporate strategy at Chiron Corporation and L.E.K. Consulting.

"I am pleased with our investors' ongoing commitment to the major clinical potential of N30 Pharma, particularly in difficult economic times. In addition, I welcome Arnie and Marc to their roles on the Board. Arnie is widely regarded as one of the premier healthcare investors in the world. Marc brings a multitude of talents and intellect to the N30 Board. I look forward to drawing on their expertise and long experience with biopharmaceutical companies as we continue to move N30 forward," commented Charles Scoggin, M.D., President and CEO of N30.

About N30 Pharma

N30 Pharma is a clinical-stage company developing s-nitrosothiol therapies for major unmet needs in cardiopulmonary diseases. S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone and inflammatory responses. N30 is a privately held company headquartered in Boulder, Colorado.

SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
7. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
11. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Post Your Comments:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
Breaking Biology News(10 mins):